Top entities: Immutep, The Schall Law Firm, United States — United States Securities and Exchange Commission.

What category does this event fall under?

Regulatory — classified as class action lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

The Schall Law Firm filed class action lawsuit Immutep · Immutep concealed trial results

Is this event still developing?

This is an active story, last updated Jun 02, 2026. Coverage continues to evolve.

Regulatory class action lawsuit

Immutep faces securities fraud lawsuit

Q: When did this event occur?

First reported May 22, 2026; last updated Jun 02, 2026.

Q: What is the market impact?

Direct. The class action lawsuit against Immutep for alleged securities fraud is likely to negatively impact Immutep's stock price and investor confidence.

Analysis based on 6 articles · First reported May 22, 2026 · Last updated Jun 02, 2026

Sentiment

-60

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit against Immutep for alleged securities fraud is likely to negatively impact Immutep's stock price and investor confidence. Investors who purchased Immutep's securities during the Class Period may seek to recover their losses, potentially leading to significant financial liabilities for Immutep.

Biotechnology Legal Services

Event Summary

The Schall Law Firm has initiated a class action lawsuit against Immutep Limited, alleging violations of the Securities Exchange Act of 1934. The lawsuit claims that Immutep made false and misleading statements to the market by concealing the true results of its TACTI-004 trial of eftilagimod alfa. Immutep reportedly claimed 'strong operational progress' in a Form-K filed with the United States — United States Securities and Exchange Commission on January 30, 2026, despite allegedly knowing the trial would fail to meet its primary efficacy endpoints. Investors who purchased Immutep's securities between March 24, 2025, and March 12, 2026, are encouraged to join the lawsuit before July 6, 2026, to recover damages.

Key Actions

100 The Schall Law Firm filed class action lawsuit Immutep

90 Immutep concealed trial results

Entities Involved

stock

Immutep

Immutep is facing a class action lawsuit for allegedly making false and misleading statements regarding its TACTI-004 trial, which could lead to significant financial and reputational damages for the company.

Importance 100 Sentiment -70

priv

The Schall Law Firm

The Schall Law Firm is initiating and leading the class action lawsuit against Immutep, representing investors who suffered losses due to the alleged securities fraud.

Importance 80 Sentiment 50

govactor

United States — United States Securities and Exchange Commission

The United States — United States Securities and Exchange Commission's rules and regulations, specifically §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, are the basis for the class action lawsuit against Immutep.

Importance 20 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard